Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Advance Notice: EastPharma Q3 2009 Results Announcement and Conference Call Invitation


Print article Print article
Refer this article Refer to a friend
Copyright © Hugin AS 2009. All rights reserved.
2009-11-09 16:00:19 -


London, November , 09, 2009
Advance Notice: EastPharma Q3 2009 Results Announcement and
Conference Call Invitation


EASTPHARMA LTD.

London, 09 November 2009 - EastPharma (EAST LI), a company active in
the manufacturing and marketing of branded generic and in-licensed
pharmaceutical products in Turkey and other regional markets, informs
that it will be announcing its Q3 2009 consolidated financial results
on 13 November 2009.

A conference call with EastPharma management will be held at 4:45pm
London time on 16th November (11:45am US East Coast time / 6:45pm
Istanbul time). Dial-in details are provided below.

Conference call:

Dailed-in Number (UK): +44 (0)20 7162 0077
Dailed-in Number (US): +1 877 491 0064
Dailed-in Number (Switzerland): +41 (0)2 2592 7007
Dailed-in Number (Germany): +49 (0)695 8999 0507
Conference ID: 850503

Participants will need to state to the operator that they are calling
for the EastPharma Earnings Results Conference Call. The recording of
this call will be available within 24 hours after the call.

For further information, please contact:
EastPharma Ltd.
Idil Bora - Investor Relations
Tel.: + 90 (212) 6929326

---END OF MESSAGE---


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


Disclaimer: © 2009 Hugin. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Hugin's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com